These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18448761)

  • 21. Bisphosphonates: a once-yearly treatment option with Reclast.
    Van Gilder D
    S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136
    [No Abstract]   [Full Text] [Related]  

  • 22. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
    Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
    Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
    Lafage-Proust MH
    Kidney Int; 2008 Sep; 74(5):557-9. PubMed ID: 18709026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.
    Wynn RL
    Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815
    [No Abstract]   [Full Text] [Related]  

  • 25. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
    Lee CY; Suzuki JB
    Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Giant cell arteritis with visual loss following zoledronic acid infusion.
    Metyas S; Ibrahim M; Solyman J; Yeter KC; Arkfeld DG
    Int J Rheum Dis; 2014 Jan; 17(1):113-5. PubMed ID: 24472274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
    Miki T; Saito S
    Clin Calcium; 2006 Jan; 16(1):167-74. PubMed ID: 16397368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
    [No Abstract]   [Full Text] [Related]  

  • 30. Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
    Gueiros LA; Lopes MA; Leão JC
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1319. PubMed ID: 18486809
    [No Abstract]   [Full Text] [Related]  

  • 31. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
    Taggart H; Cheng J; Archbold P
    Osteoporos Int; 2010 Sep; 21(9):1621-2. PubMed ID: 19813042
    [No Abstract]   [Full Text] [Related]  

  • 32. Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis.
    Mattheos N; Caldwell P; Petcu EB; Ivanovski S; Reher P
    J Can Dent Assoc; 2013; 79():d2. PubMed ID: 23763726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yearly zoledronic acid in postmenopausal osteoporosis.
    Chang JT
    N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of transient osteoporosis with intravenous zoledronate: a case report.
    Maslin D; Karanth M; Bhagat S; Guirguis R
    Int J Rheum Dis; 2014 Sep; 17(7):816-7. PubMed ID: 24673857
    [No Abstract]   [Full Text] [Related]  

  • 35. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
    Gallego L; Junquera L
    Br J Oral Maxillofac Surg; 2009 Jan; 47(1):67-8. PubMed ID: 18639371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yearly zoledronic acid in postmenopausal osteoporosis.
    Poole KE; Kaptoge S; Reeve J
    N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
    [No Abstract]   [Full Text] [Related]  

  • 37. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yearly zoledronic acid in postmenopausal osteoporosis.
    de Nijs RN; Westgeest AA
    N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824
    [No Abstract]   [Full Text] [Related]  

  • 39. Bisphosphonates and bone...what have we learned?
    Guttenberg SA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):769-72. PubMed ID: 18835534
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacist-run zoledronic acid clinic.
    Traina AN; Kane MP; Bakst G; Abelseth JM; Busch RS
    Am J Health Syst Pharm; 2011 Aug; 68(15):1399-403. PubMed ID: 21785027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.